Actively Recruiting
Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option
Led by Klinikum Esslingen · Updated on 2022-08-16
50
Participants Needed
1
Research Sites
524 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In a certified lung- cancer center, patients with NSCLC and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons. For these patients, the multidisciplinary tumor board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically including PET-CT if indicated. After review of the MDB, patients receive either definitive curative treatment or palliative treatment.
CONDITIONS
Official Title
Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed non-small cell lung cancer
- Diagnosis confirmed by histology or cytology
- Cancer stage III to IVA including oligometastatic disease
- ECOG performance status between 0 and 2
- Life expectancy of at least 3 months
- Ability to provide written informed consent
You will not qualify if you...
- Tumor is primarily resectable
- Primary definitive chemoradiotherapy is possible
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Klinikum Esslingen
Esslingen am Neckar, Germany, 73730
Actively Recruiting
Research Team
M
Martin Faehling, MD, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here